Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CSB5 | ISIN: US60853G1067 | Ticker-Symbol: 6ML0
Siehe auch MOLECULAR PARTNERS AG
Frankfurt
06.06.25 | 21:55
3,100 Euro
+3,33 % +0,100
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MOLECULAR PARTNERS AG ADR Chart 1 Jahr
5-Tage-Chart
MOLECULAR PARTNERS AG ADR 5-Tage-Chart
RealtimeGeldBriefZeit
3,0603,38006.06.

Aktuelle News zur MOLECULAR PARTNERS AG ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
19.05.Molecular Partners to Present at Upcoming Investor Conferences342ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 19, 2025AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics...
► Artikel lesen
16.05.Molecular Partners reports Q1 results2
15.05.Molecular Partners Reports Financial Results and Highlights from Q1 2025406Clinical programs on track, with two major milestones later this year, and cash position, CHF 131 million as of March 31, 2025, expected to provide funding well into 2027IND filing and initial clinical...
► Artikel lesen
MOLECULAR PARTNERS AG ADR Aktie jetzt für 0€ handeln
15.05.MOLECULAR PARTNERS AG - 6-K, Report of foreign issuer3
29.04.MOLECULAR PARTNERS AG - 6-K, Report of foreign issuer8
25.04.Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025490Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2025 First preclinical data of novel...
► Artikel lesen
16.04.Molecular Partners Announces all Board Proposals Approved at Annual General Meeting432ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 16, 2025AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics...
► Artikel lesen
25.03.Molecular Partners to hold three poster presentations at AACR 20251.284Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer First...
► Artikel lesen
25.03.Molecular Partners Publishes Invitation to Annual General Meeting 2025400ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 25, 2025AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics...
► Artikel lesen
14.03.TD Cowen maintains Buy on Molecular Partners, target CHF1510
06.03.Molecular Partners GAAP EPS of -CHF1.59, revenue of CHF5.0M1
06.03.Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024821DLL3 targeting Radio-DARPin MP0712 to enter first-in-human study in 2025, pending regulatory clearanceStrategic partnership with Orano Med on Radio-DARPins now expanded to ten programsMP0533 Phase 1/2a...
► Artikel lesen
06.03.MOLECULAR PARTNERS AG - 6-K, Report of foreign issuer1
06.03.MOLECULAR PARTNERS AG - 20-F, Annual and transition report of foreign private issuers1
28.02.Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call702Participation in fireside chats at TD Cowen and Leerink healthcare conferencesCall on 2024 financial results on March 7 at 2.00 pm CET (8.00 am ET) ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass....
► Artikel lesen
13.01.MOLECULAR PARTNERS AG - 6-K, Report of foreign issuer3
13.01.Molecular Partners und Orano dehnen Kooperation weiter aus6
13.01.Molecular Partners & Orano Med join hands for alpha radio-therapies for cancer3
12.01.Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer527New agreement enables both companies to fuel a broad and innovative pipeline of 212Pb-Radio-DARPin candidates, bringing the total number of programs up to tenExpanded partnership highlights the parties'...
► Artikel lesen
12.01.Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference626Radio-DARPin MP0712 against DLL3, in co-development with Orano Med, to enter first-in-human study in 2025Mesothelin named as second target in Radio-DARPin pipeline, program to be co-developed with Orano...
► Artikel lesen
Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1